gptkbp:instanceOf
|
gptkb:drug
|
gptkbp:approvalYear
|
2004
|
gptkbp:ATCCode
|
gptkb:N06AX21
|
gptkbp:blackBoxWarning
|
suicidal thoughts and behaviors in children, adolescents, and young adults
|
gptkbp:CASNumber
|
gptkb:136434-34-9
|
gptkbp:chemicalFormula
|
gptkb:C18H19NOS
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
uncontrolled narrow-angle glaucoma
|
gptkbp:drugClass
|
norepinephrine reuptake inhibitor
|
gptkbp:eliminationHalfLife
|
12 hours
|
gptkbp:excretion
|
urine
|
gptkbp:form
|
capsule
|
gptkbp:genericAvailable
|
yes
|
gptkbp:genericName
|
gptkb:duloxetine
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cymbalta
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:MAO_inhibitors
gptkb:SSRIs
CYP1A2 inhibitors
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
gptkbp:marketedAs
|
gptkb:United_States
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
|
gptkbp:metabolism
|
liver
|
gptkbp:patentExpired
|
2013 (US)
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:prescribes
|
adults
some adolescents (off-label)
|
gptkbp:proteinBinding
|
96%
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young adults)
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
nausea
constipation
fatigue
drowsiness
dry mouth
sexual dysfunction
decreased appetite
increased sweating
|
gptkbp:synonym
|
gptkb:duloxetine_hydrochloride
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
fibromyalgia
chronic musculoskeletal pain
diabetic peripheral neuropathic pain
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
gptkbp:bfsLayer
|
5
|